Yijieliko (Shanghai) Biotechnology Co., Ltd. Announces Completion of $60 Million Series B Financing to Accelerate Clinical Development of Epigenetic Drugs

On September 8, 2025, Yijieliko (Shanghai) Biotechnology Co., Ltd. ("Yijieliko"), a clinical-stage innovative drug development company, announced the completion of a $60 million Series B financing round. This round was led by Lapam Capital, with continued investment from existing investors Qiming Venture Partners and OrbiMed, and participation from Ganyue Investment and other well-known industry investment institutions. The funds from this round will primarily support the ongoing clinical development of the epigenetic innovative drug EPI-003 for the functional cure of chronic hepatitis B and EPI-001 for the treatment of hypercholesterolemia. Additionally, the funds will be used to rapidly advance multiple preclinical projects and further develop the technology platform, providing strong momentum for the company's in-depth research in the field of epigenetic drug development.

As a leading biotechnology company dedicated to developing the next generation of epigenetic regulation technologies for treating chronic diseases, Yijieliko (Shanghai) Biotechnology Co., Ltd. remains at the forefront of the industry. The company's proprietary EPIREG™ technology platform utilizes precise DNA methylation and histone modification to efficiently, durably, and specifically silence target genes. Compared to traditional gene-editing tools that cut DNA, this approach provides chronic disease patients with a safer, revolutionary therapeutic solution while effectively avoiding potential safety concerns associated with conventional gene editing.

Notably, Yijieliko's self-developed in vivo LNP delivery platform—EpiTax™—enables the precise delivery of EPIREG™ tools to the liver as well as multiple extrahepatic target organs. This further expands the application scope of EPIREG™ tools in disease treatment, bringing new possibilities for the treatment of more disease areas and making the company's technology portfolio more comprehensive and competitive.

In addition, the AIAID™ platform established by Yijieliko (Shanghai) Biotechnology Co., Ltd. empowers the design of epigenetic regulation drug molecules, target selection, and precise control. The platform is equipped with a self-developed foundational large model for epigenetics, providing accurate underlying data and algorithmic support. Through a multi-agent collaborative virtual laboratory, it autonomously achieves key tasks such as target discovery, target research, accessibility prediction, sgRNA design and evaluation, virtual epigenetic regulation, and multi-omics analysis. Additionally, by leveraging AI-driven de novo protein design and AI-directed evolution technology, it accelerates the discovery, iteration, and performance optimization process of EPIREG™.

Dr. Bao Hong Zhang, Co-founder and CEO of Yijieliko (Shanghai) Biotechnology Co., Ltd.Expressed: "We are very grateful for the trust and support from both new and existing investment institutions. Since the company's establishment, we have always focused on the research and transformation of epigenetic regulation technology, achieving remarkable progress in just a few years. We will continue to advance the clinical development of our core pipeline, bringing safe and effective innovative treatment solutions to patients as soon as possible."

Mr. Yu Zhihua, Chairman of Lapam Capital"Epigenetic drug development is a highly promising direction in the biotechnology field, and Yijieliko (Shanghai) Biotechnology Co., Ltd. has shown remarkable technical advantages and development potential in this area. The combination of its EPIREG™ technology platform and EpiTax™ delivery platform provides a unique solution for disease treatment. We believe that, with the support of this round of financing, Yijieliko will achieve greater breakthroughs in clinical development and technological innovation, further solidify its leading position in the epigenetics field, and bring benefits to patients worldwide."

Yijieliko (Shanghai) Biotechnology Co., Ltd. is a cutting-edge biotechnology company dedicated to treating various diseases through epigenetic regulation and developing next-generation gene modulation therapies. Founded in 2021 by a group of scientists specializing in gene modulation therapy development and seasoned experts from the pharmaceutical industry, the company has established multiple pipeline candidates covering metabolic disorders, cardiovascular diseases, viral hepatitis, ophthalmic conditions, and autoimmune diseases.

Lapam Capital, headquartered in Beijing, is a leading venture capital firm in China's biopharmaceutical industry. Lapam Capital currently manages five RMB funds and one USD fund, with a total scale exceeding 10 billion RMB. It is the only biopharmaceutical investment institution that has received investments from both of China’s top two RMB limited partners (LPs): the National Social Security Fund and the National Small and Medium Enterprise Development Fund.

Lapam Capital focuses on the fields of innovative drugs and innovative medical devices, with investment stages mainly in the early and mid-term startups. It has cumulatively invested in 200 companies, including over 160 innovative drug companies and more than 30 innovative medical device companies, such as Beta Pharma (SZ.300558), RemeGen (SH.688331; HK.09995), Aibono Neurodevices (SH.688050), Asia Pioneer Pharma (SH.688176), Kainos Medicine (SH.688687), Immunofocus (HK.01541), Contimed Pharmaceuticals (NASDAQ: GYRE), Biomed Central (HK.02563), Will Biologics (HK.09887), BinHui Biotech, Wuhe Baoao, Bendao Gene, MicroZhi Zhuo, Xinhang Road, and many other star projects.

Multiple partners of Lapam Capital's management team have over 20 years of experience in international/domestic biopharmaceutical R&D and management, providing comprehensive value-added services to their portfolio companies.

Qiming Venture Partners was founded in 2006. Currently, Qiming Venture Partners manages 11 USD funds and 7 RMB funds, with total managed assets reaching 9.5 billion USD. Since its establishment, it has focused on investing in outstanding early-stage and growth-stage companies in the Technology and Healthcare industries. To date, Qiming Venture Partners has invested in over 580 rapidly growing innovative enterprises, of which more than 210 have been listed on exchanges such as the New York Stock Exchange, NASDAQ, Hong Kong Stock Exchange, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through mergers and acquisitions. Over 80 of these enterprises have become unicorns or super unicorns recognized within their respective industries.

OrbiMed, founded in 1989, is an investment firm focused on the global biopharmaceutical sector. OrbiMed currently manages over $17 billion in assets and has successfully invested in more than 300 private companies across a wide range of healthcare fields and development stages, with over 100 companies having successfully exited. OrbiMed's secondary market investments also maintain a long-term record of outstanding returns. OrbiMed Asia, with offices in Shanghai and Mumbai, established the world’s first pan-Asian biopharmaceutical private equity fund and now manages over $2 billion in private equity funds, having invested in more than 70 companies.

Ganyue Investment (IFSC), established in 2017, is an investment firm focused on the life sciences sector. The company adheres to the investment philosophy of "basic science driving value investment" and aims to discover "technological entrepreneurs." Ganyue Capital consistently focuses on unmet clinical needs, contributing to the improvement of human health. The company has cumulatively managed over 12 funds, achieving a high success rate; out of 10 medical projects historically invested in, six companies have successfully gone public through IPOs.